Breaking News
October 24, 2018 - New 17-item questionnaire may help detect GI disorders in children with autism
October 24, 2018 - 12% of frequent marijuana smokers experience cannabis withdrawal syndrome
October 24, 2018 - Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis
October 24, 2018 - Poor Experience With PCP Linked to Hospitalization in CKD
October 23, 2018 - Dummies not to blame for common speech disorder in kids
October 23, 2018 - The future of ethics and biomedicine: An interview
October 23, 2018 - X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma
October 23, 2018 - FDA targets 465 websites that sell potentially dangerous, unapproved drugs
October 23, 2018 - New approach may lead to better diagnostic techniques for autoimmune disorders
October 23, 2018 - Innovative computer software sheds new light on genetic processes underlying deadly diseases
October 23, 2018 - Juul Drawing Lots of Teen Followers on Twitter
October 23, 2018 - WHO says Zika risk low in Pacific ahead of Meghan visit
October 23, 2018 - A deeper look at ‘Reflecting Frankenstein’
October 23, 2018 - Breastfeeding can have protective affect against high blood pressure in women, confirms study
October 23, 2018 - Epigenetic modifications may contribute to Alzheimer’s Disease
October 23, 2018 - Volunteering for peer counseling programs benefits people with lupus
October 23, 2018 - Cancer treatment may undergo a paradigm shift to immunotherapy soon
October 23, 2018 - Study uncovers new mechanism of action in a first-line drug for diabetes
October 23, 2018 - New type of molecule shows early promise against treatment-resistant prostate cancer
October 23, 2018 - Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients
October 23, 2018 - Scientists grow functioning human neural networks in 3D from stem cells
October 23, 2018 - Using mushrooms as a prebiotic may help improve glucose regulation
October 23, 2018 - New ENT clinic treats children in Zimbabwe
October 23, 2018 - CUIMC Celebrates 2018-2019, Issue 2
October 23, 2018 - Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer
October 23, 2018 - ConnectToBrain project seeks to improve techniques for brain stimulation in current clinical use
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics
October 23, 2018 - Lowering systolic blood pressure does not damage the kidneys, shows study
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
Robust Pipeline for Atopic Dermatitis

Robust Pipeline for Atopic Dermatitis

image_pdfDownload PDFimage_print

Until recently, atopic dermatitis treatments were limited primarily to topical corticosteroids and systemic immunosuppressants.

Now, however, two new therapies have reached clinical practice, and by one recent account there are at least 19 more topicals and biologics in development for atopic dermatitis.

“Our improved understanding about the mechanism for development of atopic dermatitis is leading to an expanding pipeline of new and more targeted treatment interventions,” Amy S. Paller, MD, chair of dermatology and director of the Northwestern University Skin Disease Research Center in Chicago, and colleagues wrote in a review in the Journal of Allergy and Clinical Immunology.

The emerging agents in atopic dermatitis include interleukin (IL)-4, IL-13, IgE, B-cells, IL-5, IL-31, JAK-STAT, SYK, IL-6, phosphodiesterase (PDE)-4, IL-12, IL-17, IL-23, IL-22, H4R, NKR1, κOR, TSLP, PPAR-γ, and diomogammalinolenic acid, the authors noted. In some cases, clinical trials have shown statistically significant improvements in clinical severity scores and patient-reported outcomes. In other cases, safety profiles are good, but many of these agents are in early trials.

Most Promising Atopic Dermatitis Treatments

Among the most promising new atopic dermatitis treatments are crisaborole (Eucrisa), from Pfizer, and dupilumab (Dupixent), from Regeneron, Paller et al noted. Crisaborole is a non-steroidal topical PDE-4 inhibitor approved by the FDA in 2016 for mild to moderate eczema (atopic dermatitis) in patients age 2 or older. Dupilumab is the first highly effective monoclonal antibody to be approved by the FDA. The agent targets IL-4/IL-13 and was approved early this year for adults with moderate-to-severe atopic dermatitis.

There are 12 other biologic agents under development, including nemolizumab, an anti-IL-31 receptor that specifically targets a cytokine that causes itch, which, if successful in clinical trials, would be the first biologic agent designed to control itch, the authors said.

There are six orally administered small-molecule inhibitors that have reached at least phase II trials, including baricitinib, an oral JAK1/2 inhibitor that is under study in the United States for rheumatoid arthritis. Researchers reporting at the European Academy of Dermatology and Venereology Congress earlier this year found that baricitinib improved atopic dermatitis symptoms in combination with a topical corticosteroid and serlopitant, the NK1R inhibitor being studied specifically for pruritus in atopic dermatitis.

These emerging therapies have the potential to revolutionize care, although there could be barriers to optimal clinical practice, including cost, Paller and colleagues wrote. “The extent of their effect on patient care will depend on their affordability and accessibility to patients with atopic dermatitis from a broad range of socioeconomic groups and with different insurance status.”

Long-term safety of target therapy is also an open question that requires further research, according to the authors of a review of novel therapeutic approaches to atopic dermatitis, published in August in Archivum Immunologiae et Therapiae Experimentalis.

And in another review, in the Journal of Dermatological Treatment, Vivian Shi, MD, and co-authors said that atopic dermatitis is entering a new era of target-specific treatments: “While these agents have demonstrated efficacy and potential, only dupilumab has been approved to date for adults with atopic dermatitis. Further large-scale, randomized, placebo-controlled, double-blind, multicenter trials are needed to fully evaluate the clinical benefit, safety, and cost effectiveness of these emerging therapies.”

A clear gap in the data right now is the role of novel atopic dermatitis treatments in children, which is especially important since atopic dermatitis is more prevalent in pediatric populations, the authors stated.

Further research in novel targeted atopic dermatitis therapies may be advanced by the development of the International Treatment of Atopic Eczema (TREAT) Registry Taskforce, which was started in 2017 and is designed to integrate data on systemic immunomodulatory therapies and phototherapy from dermatology communities around the world, Shi and colleagues wrote.

“The completion and continuous update of this task force will reduce heterogeneity among international clinical trial registries, allow direct comparison of data sets, and facilitate drug efficacy and safety monitoring.”

This article originally appeared on the website of our partner Dermatology Times, which is a part of UBM Medica. (Free registration is required.)

2017-11-26T11:00:00-0500

Tagged with:

About author

Related Articles